These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 27072354)

  • 1. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.
    Struemper H; Thapar M; Roth D
    Clin Pharmacokinet; 2018 Jun; 57(6):717-728. PubMed ID: 28887801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.
    Sheikh SZ; Hammer AE; Fox NL; Groark J; Struemper H; Roth D; Gordon D
    Int J Clin Pharmacol Ther; 2016 Nov; 54(11):914-922. PubMed ID: 27668697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.
    Dimelow R; Ji B; Struemper H
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):622-633. PubMed ID: 33245847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus.
    Struemper H; Chen C; Cai W
    J Clin Pharmacol; 2013 Jul; 53(7):711-20. PubMed ID: 23681782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Lupus; 2018 Jan; 27(1):112-119. PubMed ID: 28592201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus.
    Zhou X; Lee TI; Zhu M; Ma P
    Drugs R D; 2021 Dec; 21(4):407-417. PubMed ID: 34628605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
    Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective.
    Liu T; Neuner R; Thompson A; Pottackal G; Petullo D; Liu J; Nikolov N; Sahajwalla C; Doddapaneni S; Chen J
    Lupus; 2022 Apr; 31(4):424-432. PubMed ID: 35238725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study.
    Meng X; Wang Q; Wu S; Pu D; Zhang A; Fang S; Zhou X; Lu H
    Rheumatol Ther; 2021 Dec; 8(4):1711-1724. PubMed ID: 34554352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity.
    Ramachandran S; Parks D; Kurtinecz M; Roth DA; Alfonso-Cristancho R
    J Comp Eff Res; 2018 Jun; 7(6):581-593. PubMed ID: 29692179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
    Poh YJ; Baptista B; D'Cruz DP
    Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers.
    Shida Y; Takahashi N; Sakamoto T; Ino H; Endo A; Hirama T
    J Clin Pharm Ther; 2014 Feb; 39(1):97-101. PubMed ID: 24117862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis.
    Dimelow R; Liefaard L; Green Y; Tomlinson R
    Clin Pharmacokinet; 2024 Sep; 63(9):1313-1326. PubMed ID: 39320441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus.
    Dashiell-Aje E; Harding G; Pascoe K; DeVries J; Berry P; Ramachandran S
    Patient; 2018 Feb; 11(1):119-129. PubMed ID: 28956281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Struemper H; Roth D
    Mod Rheumatol; 2019 May; 29(3):452-460. PubMed ID: 29792370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
    Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
    Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.